Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E4VQ
|
|||
| Former ID |
DIB008669
|
|||
| Drug Name |
Beloranib
|
|||
| Synonyms |
251111-30-5; CKD-732; UNII-FI471K8BU6; ZGN-433; FI471K8BU6; O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol; Beloranib [INN]; ZGN 433; AC1OCFID; ZGN-440(Beloranib); US9682965, Compound A; GTPL8445; SCHEMBL14648763; DTXSID40179800; BDBM148430; ZINC3982162; AKOS027326543; DB12671; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(25)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate; O-(4-Dimethylaminoethoxycinnamoyl)fumagillol; CKD-731; Fumagillin analogs, Chong Kun Dang; HRK-429; HRK-512
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 3 | [1], [2] | |
| Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 1 | [3] | ||
| Company |
Zafgen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H41NO6
|
|||
| Canonical SMILES |
CC(=CCC1C(O1)(C)C2C(C(CCC23CO3)OC(=O)C=CC4=CC=C(C=C4)OCCN(C)C)OC)C
|
|||
| InChI |
1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1
|
|||
| InChIKey |
ZEZFKUBILQRZCK-MJSCXXSSSA-N
|
|||
| CAS Number |
CAS 251111-30-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Methionine aminopeptidase 2 (METAP2) | Target Info | Inhibitor | [3], [4] |
| Reactome | Inactivation, recovery and regulation of the phototransduction cascade | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8445). | |||
| REF 2 | ClinicalTrials.gov (NCT02179151) Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome. U.S. National Institutes of Health. | |||
| REF 3 | 2011 Pipeline of Zafgen. | |||
| REF 4 | Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes. 2014 Feb 28;7:73-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.